Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03967093 · ClinicalTrials.gov registry record · Phase 1
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
A Phase 1 study, sponsored by Bexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03967093: Clinical Trial Phase 1 study, sponsored by Bexion Pharmaceuticals.
NCT03967093 is a Phase 1 study that was terminated before completion, run by Bexion Pharmaceuticals. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03967093, a Phase 1 study, was terminated before completion, sponsored by Bexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. All patients will receive BXQ-350 by intravenous (IV) infusion. The study is divided into two parts: Part 1 will enroll patients at increasing dose levels of BXQ-350 in order to determine the MTD. Part 2 will use the MTD to further assess the safety of BXQ-350 as well as preliminary anti-tumor activity.
Primary Outcome
To determine the safety of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors, as evidenced by the incidence of treatment emergent adverse events assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Interventions
- DRUG BXQ-350
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2020-01-17 |
| Phase | Phase 1 |
Why NCT03967093 stopped before completion
NCT03967093 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which BXQ-350 is the first listed.
NCT03967093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03967093 about?
NCT03967093 is a clinical study titled "A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors". This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. All patients will receive BXQ-350 by intravenous (IV) infusion. The study is divided into two parts: Part...
What is the current status of trial NCT03967093?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-04-15. Estimated completion is 2020-01-17.
What interventions are being tested in trial NCT03967093?
The interventions under investigation include: BXQ-350 (DRUG).
Who is sponsoring clinical trial NCT03967093?
This trial is sponsored by Bexion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03967093's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI